Welcome to our dedicated page for Vitaspring Biome SEC filings (Ticker: VSBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vitaspring Biome's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vitaspring Biome's regulatory disclosures and financial reporting.
VitaSpring Biomedical Co., Ltd. reported no revenue for the three and six months ended July 31, 2025, as it remains a development-stage company focused on cell-based regenerative medicine concepts. The company recorded a net loss of $110,845 for the quarter and $191,386 for the six-month period, narrower than the prior-year losses due mainly to the elimination of lease and stock-based compensation costs.
Liquidity is extremely strained: cash was only $799, against current liabilities of $4,223,606, creating a working capital deficit of $4,215,713 and a stockholders’ deficit of $4,206,586. Related-party obligations are significant, including $2,411,000 of accounts payable to a related-party vendor and $917,020 of advances from a former CEO and other related parties. Management and the notes state that these conditions raise substantial doubt about the company’s ability to continue as a going concern, and that continued operations depend on securing additional financing and ongoing related-party support.
The company currently has no active commercial operations, no R&D spending, and has not initiated clinical trials or obtained regulatory approvals. Internal control over financial reporting was deemed ineffective due to a material weakness tied to limited personnel and lack of SEC-reporting expertise, with remediation plans dependent on future funding. As of June 17, 2026, there were 207,030,030 common shares issued and outstanding.